PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test
PacBio cut its 2026 revenue outlook as weaker instrument demand and a slower SPRQ-Nx transition raised the stakes for clinical adoption.
YahooyesterdayTMO
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
MMSI's broad portfolio, R&D investments and WRAPSODY opportunity support growth, while tariffs, China pressure and competition remain risks.
YahooyesterdayTMO
Why Is CRISPR Therapeutics (CRSP) Up 7.1% Since Last Earnings Report?
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
YahooyesterdayTMO
GEHC Wins CE Mark for Photonova Spectra, Expands International Reach
GE HealthCare's Photonova Spectra gains CE Mark, expanding access to its Deep Silicon photon-counting CT technology across Europe and other CE markets.
Yahoo2 days agoTMO
Is This the Right Time to Add PBH Stock to Your Portfolio?
Prestige Consumer Healthcare gains from acquisitions, e-commerce growth and strong cash flow, though currency swings and high debt remain key risks.
Yahoo2 days agoTMO
MBody AI Orchestrator Named Finalist for AI Deployment of the Year
MBody AI’s hardware-agnostic platform was shortlisted alongside CrowdStrike, Lenovo and CVS Health in a category recognizing real-world AI deploymentISFIYA, Israel and LAS VEGAS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- MBody AI Ltd. ("MBody AI" or the "Company") (NASDAQ: MBAI) today announced that its MBody AI Orchestrator™ platform has been shortlisted for AI Deployment of the Year in The 2026 A.I. Awards. The awards program is run by The Cloud Awards. The category recognizes the most impactful and
Yahoo2 days agoTMO
iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference
NASHVILLE, Tenn., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced participation in the upcoming Lake Street Capital Markets 10th Annual Best Ideas Growth “BIG10” Conference taking place September 10th, 2026 in New York. Event: Lake Street Capital Markets 10th Annual Best Ideas Growth “BIG10” ConferenceWho: Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea JamesDate: Thursday, September 10, 2026Location: Metropolit
Yahoo2 days agoTMO
TMO Stock Could Gain Following the Launch of EMPAD G2 Detector
Thermo Fisher's EMPAD G2 detector enhances 4D STEM imaging speed, sensitivity and workflow integration, strengthening its Analytical Instruments portfolio.
Yahoo2 days agoTMO
bioAffinity Technologies Advances CyPath Lung for Post-Treatment Lung Cancer Surveillance
The company is evaluating an additional application for CyPath Lung that could complement CT imaging when monitoring lung cancer survivors for recurrence or new primary cancers. Key Investor TakeawaysbioAffinity Technologies (NASDAQ:BIAF) is advancing CyPath Lung for potential use in post-treatment lung cancer surveillance, expanding its focus beyond early detection.
Yahoo2 days agoTMO
Tempus AI shares rise 2.7% following analyst actions
Tempus AI (NASDAQ:TEM) shares rose 2. 7% in pre-market trading following analyst actions from Piper Sandler and Canaccord Genuity as investors assessed the company’s pending acquisition of Personalis.
Yahoo3 days agoTMO
Myriad Genetics shares fall 7.1% after Piper Sandler downgrade
Myriad Genetics (NASDAQ:MYGN) shares fell 7. 1% in pre-market trading to $2.
Yahoo3 days agoTMO
Thermo Fisher Scientific to Present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026
WALTHAM, Mass., September 01, 2026--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman and chief executive officer, will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026 at 9:15 a.m. (ET).
Yahoo3 days agoTMO
Plant Virome Diagnostics Outlook 2026-2030 Featuring Profiles of Illumina, Thermo Fisher Scientific and Qiagen
Opportunities center on NGS, metagenomic profiling, portable field tests and cloud analytics, driven by viral outbreaks, precision agriculture, biosecurity and demand for early detection. Plant Virome Diagnostics Market Plant Virome Diagnostics Market Dublin, Sept. 01, 2026 (GLOBE NEWSWIRE) -- The "Plant Virome Diagnostics Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global plant virome diagnostics market is experiencing strong growth as agricultural producers, re
Yahoo3 days agoTMO
Here's How Much $1000 Invested In Thermo Fisher Scientific 10 Years Ago Would Be Worth Today
Thermo Fisher Scientific (NYSE:TMO) has outperformed the market over the past 10 years by 1.87% on an annualized basis producing an average annual return of 15.26%. Currently, Thermo Fisher Scientific has a market
Benzinga8 days agoTMO
Delta Air, Target, Thermo Fisher Scientific And A Financial Stock On CNBC’s ‘Final Trades’
Experts recommend Delta, Thermo Fisher, Target, and Interactive Brokers Group, Inc. due to strong earnings and guidance.
Benzinga9 days agoTMO
Thermo Fisher Scientific (TMO) Could Be Fully Valued On Parkinsons Proteomics Progress
Thermo Fisher Scientific (TMO) is drawing investor attention after completing Olink Explore HT proteomic analysis on about 5,500 samples from The Michael J. Fox Foundation’s Parkinson’s Precision Medicine Initiative. See our latest analysis for Thermo Fisher Scientific. The proteomics update arrives after a strong run in Thermo Fisher Scientific’s stock, with the share price at US$629.27 and a 30 day share price return of 19.53%, alongside a 1 year total shareholder return of 26.32% that...
Yahoo12 days agoTMO
Thermo Fisher Scientific (TMO) Stock Fair Value Rises After Q2 Strength And Analyst Revisions
The latest analyst work on Thermo Fisher Scientific includes a higher Fair Value Estimate that has moved from US$590.77 to US$631.42, a change of about 6.9% that feeds directly into refreshed price targets across coverage. This shift sits against a backdrop of mixed optimism and caution, as analysts weigh Q2 strength, sector updates through 2026, and the balance of growth ambition and execution risks. As you read on, you will see how this evolving narrative could shape the way you track...
Yahoo13 days agoTMO
Thermo Fisher (TMO) Stock Looks Fully Valued Following Its Microbiology Sale
Thermo Fisher Scientific stock has delivered a strong 26.3% return over the past year, yet the valuation checks suggest the shares are no longer an obvious bargain. The Discounted Cash Flow (DCF) estimate points to a level that is close to the current price, while market multiples lean richer. Over the past 12 months Thermo Fisher Scientific has returned 26.3%, which puts more pressure on today’s buyers to justify paying up at current levels. Participation in areas such as protein design...
Yahoo13 days agoTMO
XPO names chief legal officer
Former General Electric and Thermo Fisher Scientific counsel Jonas Svedlund will oversee the carrier’s legal and compliance functions.
Yahoo14 days agoTMO
Bio-Rad Gains 19.1% in the Past Month: Can Its Momentum Keep Building?
BIO's 19.1% monthly rally is backed by digital PCR gains and steadier diagnostics, but weak Life Science demand and a rich valuation loom.
Yahoo14 days agoTMO
Elon Musk Says mRNA Has ‘Tremendous’ Potential After Moderna, Merck Cancer Vaccine Breakthrough — MRNA Stock Falls Over 11% in Premarket (UPDATED)
Elon Musk said mRNA could fundamentally change disease treatment, turning medicine into a software problem.
Benzinga15 days agoTMO
Here's How Abbott's Medical Devices Arm Acts as a Growth Catalyst
ABT's Medical Devices growth is fueled by electrophysiology, expanding CGM adoption and a cardiovascular pipeline extending into 2029 and beyond.
Yahoo16 days agoTMO
Q2 Earnings Highs And Lows: Thermo Fisher (NYSE:TMO) Vs The Rest Of The Research Tools & Consumables Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how research tools & consumables stocks fared in Q2, starting with Thermo Fisher (NYSE:TMO).
Yahoo16 days agoTMO
Envetec Appoints Patrick S. Jones as Independent Director
Senior Thermo Fisher Scientific executive brings nearly 30 years of healthcare and commercial leadership to support Envetec’s global expansion Patrick S. Jones Patrick S. Jones, President of Thermo Fisher Scientific’s Clinical Diagnostics Division and independent director of Envetec Sustainable Technologies BIRDHILL, Ireland, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Envetec Sustainable Technologies Limited (Envetec), a leading sustainability innovator in clean technology for healthcare and life science
Yahoo21 days agoTMO
Thermo Fisher closes $1.1B sale of microbiology unit to PE firm
European private equity firm Astorg will run the business as an independent diagnostics company, led by former PerkinElmer CEO Dirk Bontridder.
Yahoo22 days agoTMO
Stronger Q2 Results And New Supply Deal Might Change The Case For Investing In LivaNova (LIVN)
LivaNova PLC recently reported second-quarter 2026 results showing sales rising to US$390.59 million and net income climbing to US$108.57 million, alongside higher earnings per share versus a year earlier. On the back of this performance, the company raised its 2026 constant-currency revenue growth guidance to a range of 8% to 9% and secured a long-term oxygenator supply agreement with Thermo Fisher Scientific to support manufacturing expansion. Now we’ll examine how the raised 2026 growth...
Yahoo22 days agoTMO
LivaNova (LIVN) Could Be 5% Undervalued Following Raised 2026 Guidance
LivaNova (LIVN) raised its full year 2026 revenue and earnings guidance after reporting record quarterly revenue and significantly higher profitability, supported by demand for its Essenz heart-lung machine and a new supply agreement with Thermo Fisher Scientific. See our latest analysis for LivaNova. LivaNova's recent guidance lift comes after a strong run in the share price, with a 90 day share price return of 12.71% and a year to date share price return of 33.21%. The 1 year total...
Yahoo22 days agoTMO
Astorg Completes Acquisition of Microbiology Business From Thermo Fisher Scientific, Establishing an Independent Global Diagnostics Specialist
LUXEMBOURG & NEW YORK & PARIS, August 12, 2026--Astorg, a leading pan-European private equity firm, today announced the successful completion of its acquisition of the global microbiology business from Thermo Fisher Scientific. The business will now operate as an independent company under the leadership of Chief Executive Officer Dirk Bontridder and will launch under a new corporate brand later in 2026.
Yahoo23 days agoTMO
Thermo Fisher Scientific Completes Sale of its Microbiology Business to Astorg
WALTHAM, Mass., August 12, 2026--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed the sale of its microbiology business to Astorg, a leading pan-European private equity firm, for consideration of approximately $1.075 billion, consisting of cash and a $50 million seller note.
Yahoo23 days agoTMO
Following Hamamatsu's Rebranding of NKT Photonics to Drive Laser Innovation, New Biophotonics Market Overview Maps Strategic Growth Through 2030
Accelerating momentum across major industry heavyweights—highlighted by Thermo Fisher Scientific’s Q2 2026 revenue beat, Hamamatsu Photonics’ launch of its dedicated Lasers & Fibers Business Unit, and BD’s $4.98 billion Q3 performance—is driving rapid adoption of optical diagnostic and imaging solutions worldwide. This report provides an in-depth analysis of key technological advancements, regional market shares, and competitive strategies across the global biophotonics sector. Biophotonics Mark
Yahoo23 days agoTMO
Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline
Arcturus Therapeutics (NASDAQ:ARCT) is positioning its mRNA platform around two rare-disease programs targeting cystic fibrosis and ornithine transcarbamylase deficiency, while its vaccine business is intended to help support therapeutic development, President and CEO Joseph Payne said during a Cana
Yahoo23 days agoTMO